Phase 2 data from PTC Therapeutics showed that the Novartis-partnered Huntington’s disease asset slowed progression by more ...
PTC Therapeutics Inc. PTCT shares are tumbling on Wednesday, after the company reported topline results from the 24-month ...
PTC Therapeutics (NASDAQ:PTCT) reported top-line results from a 24-month interim analysis of the PIVOT-HD long-term extension (LTE) study evaluating Votoplam in Huntington’s disease, highlighting what ...
Dose-dependent benefit on cUHDRS in Stage 2 participants compared to matched natural history cohort, with 52% slowing at 10 mg dose - - Continued evidence of favorable ...
PTC Therapeutics, Inc. (NASDAQ:PTCT) on Monday announced results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington’s disease (HD) patients. Huntington’s disease is ...
PTC (NASDAQ: PTC) today announced the release of Windchill AI Assistant, a new artificial intelligence (AI) capability built ...
Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, today announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results